Literature DB >> 2864253

Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Predictors and influence of neuroleptic treatment.

W Gaebel, A Pietzcker.   

Abstract

Several dimensions of the outcome of 86 schizophrenic patients were recorded 1 year after discharge from inpatient index-treatment to complete a prospective study concerning the course of illness (rehospitalization, symptoms, employment and social contacts). When compared with 75 psychiatric patients of other diagnostic groups, no differences were found other than a significantly longer average rehospitalization stay for the schizophrenic patients. Taking prognostic categories and the regularity of neuroleptic therapy conducted during follow-up into account, it was established that the social outcome status of schizophrenic patients is substantially determined by the original level at the time of index-treatment. In contrast, the rate of relapse and readmission depend significantly upon the continuity of neuroleptic treatment. More complex analyses show that particularly for patients already hospitalized several times, successful relapse prophylactic treatment also has a favorable influence upon the patients' symptoms in the sense of a more stable remission. This could be related to the finding that the more chronic patients apparently exhibit a delayed remission when they undergo a relapse. The findings are interpreted to the effect that continuous neuroleptic maintenance therapy is advantageous to the majority of the patients, and should be applied, in view of the fact that alternative therapy procedures such as neuroleptic interval strategies have not yet been sufficiently evaluated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864253     DOI: 10.1007/bf00380969

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  22 in total

1.  Premorbid adjustment in schizophrenia: concepts, measures, and implications. Part I. The concept of premorbid adjustment.

Authors:  J S Strauss; R F Kokes; R Klorman; J L Sacksteder
Journal:  Schizophr Bull       Date:  1977       Impact factor: 9.306

2.  Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community.

Authors:  B C Stevens
Journal:  Psychol Med       Date:  1973-05       Impact factor: 7.723

3.  Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients.

Authors:  G E Hogarty; S C Goldberg; N R Schooler
Journal:  Arch Gen Psychiatry       Date:  1974-11

4.  Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors.

Authors:  J S Strauss; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  1977-02

5.  Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine.

Authors:  T R Barnes; G Milavic; D A Curson; S D Platt
Journal:  Soc Psychiatry       Date:  1983

Review 6.  Predicting the outcome in schizophrenia.

Authors:  R C Bland
Journal:  Can J Psychiatry       Date:  1982-02       Impact factor: 4.356

7.  Early intervention, time-limited, targeted pharmacotherapy of schizophrenia.

Authors:  W T Carpenter; D W Heinrichs
Journal:  Schizophr Bull       Date:  1983       Impact factor: 9.306

8.  Important issues in the drug treatment of schizophrenia.

Authors:  J M Davis; C B Schaffer; G A Killian; C Kinard; C Chan
Journal:  Schizophr Bull       Date:  1980       Impact factor: 9.306

9.  Organizing the complexes of schizophrenia.

Authors:  J S Strauss; L Loevsky; W Glazer; P Leaf
Journal:  J Nerv Ment Dis       Date:  1981-02       Impact factor: 2.254

10.  A 15-year followup of 646 schizophrenic outpatients.

Authors:  D M Engelhardt; B Rosen; J Feldman; J A Engelhardt; P Cohen
Journal:  Schizophr Bull       Date:  1982       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.